Stephen L. Rawlings

Array ( [id] => 12675958 [patent_doc_number] => 20180117152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => ANTI-CD3 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/836107 [patent_app_country] => US [patent_app_date] => 2017-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -106 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15836107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15615993 [patent_doc_number] => 20200078401 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-12 [patent_title] => COMPOSITIONS FOR CANCER TREATMENT AND METHODS AND USES FOR CANCER TREATMENT AND PROGNOSIS [patent_app_type] => utility [patent_app_number] => 16/465983 [patent_app_country] => US [patent_app_date] => 2017-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56881 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -117 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408061 [patent_doc_number] => 20200024352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => ANTI-TIM-3 ANTIBODIES FOR COMBINATION WITH ANTI-PD-L1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/346769 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17363579 [patent_doc_number] => 11230596 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-25 [patent_title] => Methods for treatment of cancer comprising TIGIT-binding agents [patent_app_type] => utility [patent_app_number] => 16/464820 [patent_app_country] => US [patent_app_date] => 2017-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 43960 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16464820 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254237 [patent_doc_number] => 20190375852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/462710 [patent_app_country] => US [patent_app_date] => 2017-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16462710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12808774 [patent_doc_number] => 20180161428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => Prostate Specific Membrane Antigen Binding Protein [patent_app_type] => utility [patent_app_number] => 15/821498 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16460799 [patent_doc_number] => 10844134 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => PSMA targeting trispecific proteins and methods of use [patent_app_type] => utility [patent_app_number] => 15/821530 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 24 [patent_no_of_words] => 15279 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12233169 [patent_doc_number] => 20180066033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'TARGETING TRASTUZUMAB-RESISTANT HER2+ BREAST CANCER WITH A HER3-TARGETING NANOPARTICLE' [patent_app_type] => utility [patent_app_number] => 15/816881 [patent_app_country] => US [patent_app_date] => 2017-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 20496 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15816881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12711001 [patent_doc_number] => 20180128833 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => METHODS OF TREATING WITH TUMOR MEMBRANE VESICLE-BASED IMMUNOTHERAPY AND PREDICTING THERAPEUTIC RESPONSE THERETO [patent_app_type] => utility [patent_app_number] => 15/807050 [patent_app_country] => US [patent_app_date] => 2017-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17929 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15807050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12750553 [patent_doc_number] => 20180142018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => ANTI-CD19 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/804517 [patent_app_country] => US [patent_app_date] => 2017-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15804517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527283 [patent_doc_number] => 20200055947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => BI-SPECIFIC ACTIVATORS FOR TUMOR THERAPY [patent_app_type] => utility [patent_app_number] => 16/347202 [patent_app_country] => US [patent_app_date] => 2017-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14926269 [patent_doc_number] => 20190298772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => COMBINATION THERAPY OF A T CELL-BASED THERAPY AND A BTK INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/346528 [patent_app_country] => US [patent_app_date] => 2017-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83828 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -177 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12728914 [patent_doc_number] => 20180134805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES [patent_app_type] => utility [patent_app_number] => 15/796361 [patent_app_country] => US [patent_app_date] => 2017-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15796361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038715 [patent_doc_number] => 20190330362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => CD133-BINDING AGENTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/342807 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24873 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16342807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219233 [patent_doc_number] => 20180057593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'MASKED ANTI-CD3 ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/787922 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 35300 [patent_no_of_claims] => 125 [patent_no_of_ind_claims] => 37 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15787922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17207983 [patent_doc_number] => 11168344 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-09 [patent_title] => Methods for producing polypeptides by regulating polypeptide association [patent_app_type] => utility [patent_app_number] => 15/782256 [patent_app_country] => US [patent_app_date] => 2017-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 34634 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15782256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14652767 [patent_doc_number] => 20190233512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => ANTI-FOLATE RECEPTOR ANTIBODIES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODIES AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/341015 [patent_app_country] => US [patent_app_date] => 2017-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12160301 [patent_doc_number] => 20180031567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'MULTIPLEX ASSAY FOR IMPROVED SCORING OF TUMOR TISSUES STAINED FOR PD-L1' [patent_app_type] => utility [patent_app_number] => 15/726377 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10912 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15726377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12178718 [patent_doc_number] => 20180037654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'NEW ANTI-HCTLA-4 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/665858 [patent_app_country] => US [patent_app_date] => 2017-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 51799 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15665858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13399991 [patent_doc_number] => 20180251538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => NOVEL ANTI-IL13 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/721570 [patent_app_country] => US [patent_app_date] => 2017-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15721570 [rel_patent_id] =>[rel_patent_doc_number] =>)